Adicet Bio, Inc.

DB:1IJ Stock Report

Market Cap: €90.5m

Adicet Bio Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Chen Schor

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage44.09%
CEO tenure6yrs
CEO ownership0.1%
Management average tenure5.7yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chen Schor's remuneration changed compared to Adicet Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$99m

Mar 31 2026n/an/a

-US$109m

Dec 31 2025US$1mUS$646k

-US$117m

Sep 30 2025n/an/a

-US$115m

Jun 30 2025n/an/a

-US$119m

Mar 31 2025n/an/a

-US$117m

Dec 31 2024US$5mUS$628k

-US$117m

Sep 30 2024n/an/a

-US$118m

Jun 30 2024n/an/a

-US$137m

Mar 31 2024n/an/a

-US$140m

Dec 31 2023n/an/a

-US$143m

Sep 30 2023n/an/a

-US$143m

Jun 30 2023n/an/a

-US$115m

Mar 31 2023n/an/a

-US$105m

Dec 31 2022US$4mUS$562k

-US$70m

Sep 30 2022n/an/a

-US$56m

Jun 30 2022n/an/a

-US$48m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$10mUS$536k

-US$62m

Sep 30 2021n/an/a

-US$55m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$11mUS$499k

-US$37m

Compensation vs Market: Chen's total compensation ($USD1.47M) is above average for companies of similar size in the German market ($USD396.26K).

Compensation vs Earnings: Chen's compensation has been consistent with company performance over the past year.

CEO

Chen Schor (54 yo)

6yrs
Tenure
US$1,465,747
Compensation

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...

Leadership Team

NamePositionTenureCompensationOwnership
Chen Schor
CEO, President & Director6yrsUS$1.47m0.11%
€ 95.9k
Blake Aftab
Senior VP & Chief Scientific Officer5.4yrsUS$915.49k0.024%
€ 21.6k
Lloyd Klickstein
Interim Chief Medical Officer & Directorless than a yearUS$64.35k0.060%
€ 53.9k
Brian Harvey
Chief Financial Officer6yrsUS$1.52m0.043%
€ 38.6k
Donald Healey
Chief Technology Officer5.9yrsUS$2.09m0.028%
€ 25.6k
Amy Locke
Chief Human Resource Officer4.7yrsno datano data
5.7yrs
Average Tenure
64yo
Average Age

Experienced Management: 1IJ's management team is seasoned and experienced (5.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chen Schor
CEO, President & Director6yrsUS$1.47m0.11%
€ 95.9k
Lloyd Klickstein
Interim Chief Medical Officer & Director2.1yrsUS$64.35k0.060%
€ 53.9k
Steve Dubin
Independent Director6yrsUS$82.11k0.0097%
€ 8.8k
Andrew Sinclair
Lead Independent Director5.5yrsUS$97.03k0.0069%
€ 6.2k
Jeffrey Chodakewitz
Independent Director6yrsUS$68.88k0.0069%
€ 6.2k
Marco Davila
Member of Scientific Advisory Board5.2yrsno datano data
Michael Grissinger
Independent Director1.4yrsUS$59.63k0%
€ 0
Michael Kalos
Member of Scientific Advisory Board5.2yrsno datano data
Saul Priceman
Member of Scientific Advisory Board5.2yrsno datano data
Constantine Mitsiades
Member of Scientific Advisory Board5.2yrsno datano data
Katie Peng
Independent Director3.2yrsUS$67.85k0.0034%
€ 3.1k
5.2yrs
Average Tenure
69yo
Average Age

Experienced Board: 1IJ's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 16:10
End of Day Share Price 2026/09/15 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adicet Bio, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Yatin SunejaGuggenheim Securities, LLC